Rani Historical Income Statement
| RANI Stock | USD 1.31 0.01 0.76% |
Historical analysis of Rani Therapeutics income statement accounts such as Total Revenue of 0.0, Other Operating Expenses of 50.4 M, Research Development of 30.7 M or Total Operating Expenses of 50.4 M can show how well Rani Therapeutics Holdings performed in making a profits. Evaluating Rani Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Rani Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Rani Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Rani Therapeutics is a good buy for the upcoming year.
Rani |
About Rani Income Statement Analysis
Rani Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Rani Therapeutics shareholders. The income statement also shows Rani investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Rani Therapeutics Income Statement Chart
Add Fundamental
Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Cost Of Revenue
Cost of Revenue is found on Rani Therapeutics income statement and represents the costs associated with goods and services Rani Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Rani Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Rani Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rani Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. As of now, Rani Therapeutics' Interest Income is increasing as compared to previous years. The Rani Therapeutics' current Interest Expense is estimated to increase to about 6.1 M, while Tax Provision is forecasted to increase to (35.1 K).
| 2022 | 2023 | 2024 | 2025 (projected) | Depreciation And Amortization | 1.3M | 822K | 945.3K | 925.5K | Interest Income | 1.2M | 3.4M | 4.0M | 4.2M |
Rani Therapeutics income statement Correlations
Click cells to compare fundamentals
Rani Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Rani Therapeutics income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Tax Provision | 35K | 41K | 70K | (41K) | (36.9K) | (35.1K) | |
| Net Interest Income | (61K) | (377K) | 177K | (1.1M) | (957.6K) | (909.7K) | |
| Interest Income | 63K | 89K | 1.2M | 3.4M | 4.0M | 4.2M | |
| Depreciation And Amortization | 589K | 497K | 1.3M | 822K | 945.3K | 925.5K | |
| Interest Expense | 124K | 466K | 1.1M | 5.1M | 5.8M | 6.1M | |
| Selling General Administrative | 5.0M | 27.8M | 26.8M | 26.5M | 30.4M | 19.7M | |
| Gross Profit | 462K | 2.7M | (1.3M) | (822K) | (739.8K) | (702.8K) | |
| Other Operating Expenses | 17.0M | 54.3M | 63.5M | 66.1M | 76.0M | 50.4M | |
| Operating Income | (16.5M) | (51.6M) | (63.5M) | (66.1M) | (59.5M) | (62.5M) | |
| Net Income From Continuing Ops | (16.7M) | (53.1M) | (63.3M) | (71.2M) | (64.1M) | (67.3M) | |
| Ebit | (16.5M) | (52.6M) | (62.2M) | (66.1M) | (59.5M) | (62.5M) | |
| Research Development | 12.0M | 26.5M | 36.6M | 39.6M | 45.6M | 30.7M | |
| Ebitda | (16.0M) | (52.1M) | (60.9M) | (65.3M) | (58.7M) | (61.7M) | |
| Total Operating Expenses | 17.0M | 54.3M | 63.5M | 66.1M | 76.0M | 50.4M | |
| Reconciled Depreciation | 589K | 497K | 548K | 769K | 884.4K | 652.7K | |
| Income Before Tax | (16.7M) | (53.0M) | (63.3M) | (67.9M) | (61.1M) | (64.1M) | |
| Total Other Income Expense Net | (124K) | (1.4M) | 177K | (1.8M) | (1.6M) | (1.5M) | |
| Net Income | (16.7M) | (53.1M) | (63.3M) | (34.0M) | (30.6M) | (32.1M) | |
| Income Tax Expense | 35K | 41K | 70K | (33.9M) | (30.5M) | (29.0M) |
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rani Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.